Document Detail


Neoadjuvant chemotherapy cannot be regarded as adequate routine therapy strategy of advanced ovarian cancer.
MedLine Citation:
PMID:  22274314     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
ABSTRACT: Minority vote to statement A5 of the Fourth Ovarian Cancer Consensus Conference, Vancouver 2010, on behalf of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Germany plus North-Eastern Society of Gyneco-Oncology and the AGO Austria.
Authors:
Andreas du Bois; Christian Marth; Jacobus Pfisterer; Philipp Harter; Felix Hilpert; Alain G Zeimet; Jalid Sehouli
Related Documents :
17167974 - Effect of immunotherapy and spleen preservation on immunological function in patients w...
20952724 - Review. colon cancer vaccines: an update.
12946654 - Circadian disruption in cancer: a neuroendocrine-immune pathway from stress to disease?
14967074 - Future directions: oncolytic viruses.
21663394 - A novel bioluminescence orthotopic mouse model for advanced lung cancer.
12496764 - Fingerprinting the circulating repertoire of antibodies from cancer patients.
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  International journal of gynecological cancer : official journal of the International Gynecological Cancer Society     Volume:  22     ISSN:  1525-1438     ISO Abbreviation:  Int. J. Gynecol. Cancer     Publication Date:  2012 Feb 
Date Detail:
Created Date:  2012-01-25     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9111626     Medline TA:  Int J Gynecol Cancer     Country:  United States    
Other Details:
Languages:  eng     Pagination:  182-5     Citation Subset:  IM    
Affiliation:
*Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Studiengruppe, Germany; and †Arbeitsgemeinschaft Gynaekologische Onkologie, Austria.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The Option of HBIG-Free Prophylaxis Against Recurrent HBV.
Next Document:  Association of interleukin 16 with the development of ovarian tumor and tumor-associated neoangiogen...